Logo image of ABVX

ABIVAX SA-ADR (ABVX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABVX - US00370M1036 - ADR

119.92 USD
-4.91 (-3.93%)
Last: 12/1/2025, 8:00:00 PM
121.134 USD
+1.21 (+1.01%)
Pre-Market: 12/2/2025, 8:00:02 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ABVX. ABVX was compared to 534 industry peers in the Biotechnology industry. ABVX has a bad profitability rating. Also its financial health evaluation is rather negative. ABVX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ABVX has reported negative net income.
In the past 5 years ABVX always reported negative net income.
ABVX had a negative operating cash flow in each of the past 5 years.
ABVX Yearly Net Income VS EBIT VS OCF VS FCFABVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ABVX has a Return On Assets of -105.39%. This is in the lower half of the industry: ABVX underperforms 76.22% of its industry peers.
Industry RankSector Rank
ROA -105.39%
ROE N/A
ROIC N/A
ROA(3y)-74.5%
ROA(5y)-62.73%
ROE(3y)-491.9%
ROE(5y)-484.88%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX Yearly ROA, ROE, ROICABVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

ABVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX Yearly Profit, Operating, Gross MarginsABVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ABVX has about the same amount of shares outstanding.
Compared to 5 years ago, ABVX has more shares outstanding
Compared to 1 year ago, ABVX has a worse debt to assets ratio.
ABVX Yearly Shares OutstandingABVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABVX Yearly Total Debt VS Total AssetsABVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ABVX has an Altman-Z score of 20.33. This indicates that ABVX is financially healthy and has little risk of bankruptcy at the moment.
ABVX has a better Altman-Z score (20.33) than 89.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 20.33
ROIC/WACCN/A
WACCN/A
ABVX Yearly LT Debt VS Equity VS FCFABVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.25 indicates that ABVX should not have too much problems paying its short term obligations.
ABVX has a Current ratio of 1.25. This is amonst the worse of the industry: ABVX underperforms 84.27% of its industry peers.
ABVX has a Quick Ratio of 1.25. This is a normal value and indicates that ABVX is financially healthy and should not expect problems in meeting its short term obligations.
ABVX has a Quick ratio of 1.25. This is amonst the worse of the industry: ABVX underperforms 83.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.25
ABVX Yearly Current Assets VS Current LiabilitesABVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.37% over the past year.
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.94% yearly.
Based on estimates for the next years, ABVX will show a very strong growth in Revenue. The Revenue will grow by 179.09% on average per year.
EPS Next Y-3.38%
EPS Next 2Y32.6%
EPS Next 3Y-2.16%
EPS Next 5Y35.94%
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y179.09%

3.3 Evolution

ABVX Yearly Revenue VS EstimatesABVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
ABVX Yearly EPS VS EstimatesABVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX Price Earnings VS Forward Price EarningsABVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX Per share dataABVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

A cheap valuation may be justified as ABVX's earnings are expected to decrease with -2.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.6%
EPS Next 3Y-2.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIVAX SA-ADR

NASDAQ:ABVX (12/1/2025, 8:00:00 PM)

Premarket: 121.134 +1.21 (+1.01%)

119.92

-4.91 (-3.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-08 2025-09-08/amc
Earnings (Next)12-15 2025-12-15
Inst Owners44%
Inst Owner Change67.63%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.33B
Revenue(TTM)N/A
Net Income(TTM)-176.00M
Analysts85.71
Price Target123.46 (2.95%)
Short Float %2.39%
Short Ratio1.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.87%
PT rev (3m)46.44%
EPS NQ rev (1m)0.6%
EPS NQ rev (3m)3.17%
EPS NY rev (1m)-7.7%
EPS NY rev (3m)-3.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)2.26%
Revenue NY rev (3m)-14.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.64
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.1
TBVpS-0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -105.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.5%
ROA(5y)-62.73%
ROE(3y)-491.9%
ROE(5y)-484.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.25
Altman-Z 20.33
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.27%
Cap/Depr(5y)310.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.06%
EPS Next Y-3.38%
EPS Next 2Y32.6%
EPS Next 3Y-2.16%
EPS Next 5Y35.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y179.09%
EBIT growth 1Y-36.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.19%
EBIT Next 3Y16.39%
EBIT Next 5Y40.7%
FCF growth 1Y-58.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.76%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA-ADR / ABVX FAQ

What is the fundamental rating for ABVX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ABVX.


What is the valuation status for ABVX stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIVAX SA-ADR (ABVX). This can be considered as Overvalued.


How profitable is ABIVAX SA-ADR (ABVX) stock?

ABIVAX SA-ADR (ABVX) has a profitability rating of 0 / 10.


What is the financial health of ABIVAX SA-ADR (ABVX) stock?

The financial health rating of ABIVAX SA-ADR (ABVX) is 3 / 10.